Search research articles
Contact Us
Filters
Showing results (191-200 of 218) with videos related to
Page
of 22
Sort By:
The British Journal of Dermatology
|
January 20, 2016
Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
V J Ludbrook, K J Hicks, K E Hanrott, et al.
The British Journal of Dermatology
|
April 10, 2021
Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study
J-T Maul, M Augustin, C Sorbe, et al.
The British Journal of Dermatology
|
March 17, 2017
Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations
A Blauvelt, C E M Griffiths, M Lebwohl, et al.
Journal of Medical Genetics
|
June 16, 2009
Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1
U Hüffmeier, J Lascorz, T Becker, et al.
The British Journal of Dermatology
|
December 2, 2017
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)
M de Bruin-Weller, D Thaçi, C H Smith, et al.
Experimental Dermatology
|
September 28, 2006
Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes?
J M Schröder, K Reich, K Kabashima, et al.
The British Journal of Dermatology
|
February 5, 2021
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)
D Thaci, S Piaserico, R B Warren, et al.
The British Journal of Dermatology
|
December 31, 2019
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial
A Blauvelt, K Papp, A Gottlieb, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 15, 2023
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study
K Reich, J I Silverberg, K A Papp, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 14, 2020
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
T Bieber, J P Thyssen, K Reich, et al.
Page
of 22
Search research articles
Search
Showing results (191-200 of 218) with videos related to
Sort By:
Page
of 22
The British Journal of Dermatology
|
January 20, 2016
Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
V J Ludbrook, K J Hicks, K E Hanrott, et al.
The British Journal of Dermatology
|
April 10, 2021
Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study
J-T Maul, M Augustin, C Sorbe, et al.
The British Journal of Dermatology
|
March 17, 2017
Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations
A Blauvelt, C E M Griffiths, M Lebwohl, et al.
Journal of Medical Genetics
|
June 16, 2009
Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1
U Hüffmeier, J Lascorz, T Becker, et al.
The British Journal of Dermatology
|
December 2, 2017
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)
M de Bruin-Weller, D Thaçi, C H Smith, et al.
Experimental Dermatology
|
September 28, 2006
Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes?
J M Schröder, K Reich, K Kabashima, et al.
The British Journal of Dermatology
|
February 5, 2021
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)
D Thaci, S Piaserico, R B Warren, et al.
The British Journal of Dermatology
|
December 31, 2019
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial
A Blauvelt, K Papp, A Gottlieb, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 15, 2023
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study
K Reich, J I Silverberg, K A Papp, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 14, 2020
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
T Bieber, J P Thyssen, K Reich, et al.
Page
of 22